- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| COILED THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Coiled Therapeutics - Issue of Equity | - | RNS | ||
| 27.05. | Coiled Therapeutics - Notice of Annual General Meeting | - | RNS | ||
| 19.05. | Coiled Therapeutics shares rise as cross trading begins in New York | 1 | Alliance News | ||
| 19.05. | Coiled Therapeutics startet Handel am US-Markt OTCQB | 1 | Investing.com Deutsch | ||
| 19.05. | Coiled Therapeutics begins trading on US OTCQB market | 2 | Investing.com | ||
| 19.05. | Coiled Therapeutics - Commencement of Trading on US OTCQB Venture Market | - | RNS | ||
| 07.05. | Coiled Therapeutics präsentiert auf New Yorker Accelerator-Programm | 1 | Investing.com Deutsch | ||
| 07.05. | Coiled Therapeutics presents at NY accelerator program | 1 | Investing.com | ||
| 07.05. | Coiled Therapeutics - Attendance at Endless Frontier Labs 2026 | - | RNS | ||
| 07.05. | Coiled Therapeutics - Appointment of Non-Executive Director | - | RNS | ||
| 06.05. | Coiled Therapeutics reports strategic shift to oncology assets | 1 | Investing.com | ||
| 06.05. | Coiled Therapeutics - Annual Report & Financial Statements | - | RNS | ||
| 15.04. | Coiled Therapeutics - Presentation at 18th Annual World Cancer Congress | 2 | RNS | ||
| 08.04. | IN BRIEF: Coiled Therapeutics shares jump as hails inhibitor benefit | 1 | Alliance News | ||
| 08.04. | Coiled Therapeutics - Clinical Trial Update | - | RNS | ||
| 27.03. | Roquefort springs over to AIM from Main Market as Coiled Therapeutics | 2 | Alliance News | ||
| 27.03. | Roquefort Therapeutics plc - Removal | 338 | Dow Jones News | DJ Roquefort Therapeutics plc - Removal
Financial Conduct Authority (-)
Roquefort Therapeutics plc - Removal
27-March-2026 / 08:00 GMT/BST
=----------------------------------------------------------------------------------------------------------------------... ► Artikel lesen | |
| 27.03. | Stock Exch Notice - Readmission - Roquefort Therapeutics Plc | 5 | RNS | ||
| 27.03. | Coiled Therapeutics startet nach Kapitalerhöhung über 8,5 Mio. Pfund am AIM | 5 | Investing.com Deutsch | ||
| 27.03. | Coiled Therapeutics begins trading on AIM after £8.5m raise | 4 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 258,08 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,690 | -0,06 % | Relay Therapeutics Shares Jump 18% | ||
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| COGENT BIOSCIENCES | 32,760 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| QIAGEN | 30,705 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| ERASCA | 13,480 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,300 | +0,13 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,505 | +0,02 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,71 | 0,00 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,615 | +0,14 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| FULCRUM THERAPEUTICS | 3,140 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | ? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik- (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk... ► Artikel lesen | |
| ABIVAX | 63,20 | -0,32 % | Abivax mit Daten: Erst Rakete, dann Absturz - erhöht Obefazimod das Krebsrisiko? | Die Aktie von Abivax hat am Montagabend genau die Nachricht geliefert, auf die Investoren seit Monaten gewartet hatten. Das französische Biotech-Unternehmen präsentierte herausragende Topline-Ergebnisse... ► Artikel lesen | |
| IMMUNOVANT | 30,920 | 0,00 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data | ||
| OLEMA PHARMACEUTICALS | 10,690 | 0,00 % | Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer | Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results... ► Artikel lesen | |
| BIONTECH | 76,30 | -3,72 % | Vorsicht bei BioNTech! Novo Nordisk gibt Gas! Kaufchance bei Vidac Pharma Aktie! | Kaufstimmung bei Novo Nordisk. Die Aktie des dänischen Pharmagiganten scheint den seit Sommer 2024 begonnenen Abwärtstrend zu verlassen. Anleger reagieren auf positive Meldungen. Bei Vidac Pharma ist... ► Artikel lesen |
Das Unternehmen COILED THERAPEUTICS PLC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +9,62 % bei einem Aktienkurs von 0,116 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COILED THERAPEUTICS PLC finden Sie auf Wallstreet Online.